GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MoonLake Immunotherapeutics (NAS:MLTX) » Definitions » Institutional Ownership

MoonLake Immunotherapeutics (MoonLake Immunotherapeutics) Institutional Ownership : 25.52% (As of May. 24, 2024)


View and export this data going back to 2022. Start your Free Trial

What is MoonLake Immunotherapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, MoonLake Immunotherapeutics's institutional ownership is 25.52%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, MoonLake Immunotherapeutics's Insider Ownership is 5.64%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, MoonLake Immunotherapeutics's Float Percentage Of Total Shares Outstanding is 41.06%.


MoonLake Immunotherapeutics Institutional Ownership Historical Data

The historical data trend for MoonLake Immunotherapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MoonLake Immunotherapeutics Institutional Ownership Chart

MoonLake Immunotherapeutics Historical Data

The historical data trend for MoonLake Immunotherapeutics can be seen below:

2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Institutional Ownership 27.46 26.62 28.34 29.12 25.53 26.55 26.57 25.44 25.99 25.52

MoonLake Immunotherapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


MoonLake Immunotherapeutics (MoonLake Immunotherapeutics) Business Description

Traded in Other Exchanges
Address
Dorfstrasse 29, Zug, CHE, 6300
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.
Executives
Matthias Bodenstedt officer: Chief Financial Officer DORFSTRASSE 29, ZUG V8 6300
Bihua Chen 10 percent owner C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iv Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iii Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Ii, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Simon Sturge director DORFSTRASSE 29, ZUG V8 6300
Kristian Reich officer: Chief Scientific Officer DORFSTRASSE 29, ZUG V8 6300
Santos Da Silva Jorge director, officer: Chief Executive Officer DORFSTRASSE 29, ZUG V8 6300
Bvf Partners L P/il director, 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Andrew John Phillips director C/O CORMORANT ASSET MANAGEMENT, LLP, 200 CLARENDON STREET, FL 52, BOSTON MA 02116
Ramnik Xavier director DORFSTRASSE 29, ZUG V8 6300
Spike Loy director DORFSTRASSE 29, ZUG V8 6300
Kara Lassen director DORFSTRASSE 29, ZUG V8 6300

MoonLake Immunotherapeutics (MoonLake Immunotherapeutics) Headlines

From GuruFocus